Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 234-236

  Rusconi, Stefano ^a,d   Moonis, Mona ^a   Merrill, Debra P ^a   Pallai, Peter V ^b   Neidhardt, Edith A ^b   Singh, Shyam K ^b   Willis, Kevin J ^b   Osburne, Marcia S ^b   Profy, Albert T ^b   Jenson, James C ^b   Hirsch, Martin S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Procept Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NAPHTHALENE DERIVATIVE; PIC 024 4; POLYMER; PRO 2000; SULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL;

EID: 13344262687     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.234     Document Type: Article

References (23)

1. Arulanandam, A. R. N., P. Moingeon, M. F. Concino, M. A. Recny, K. Kato, H. Yagita, S. Koyasu, and E. L. Reinherz. 1993. A soluble multimeric recombinant CD2 protein identifies CD4S as a low affinity ligand for human CD2: divergence of CD2 ligands during the evolution of humans and mice. J Exp. Med. 177:1439-1450.
2. Callahan, L. N., M. Phelan, M. Mallinson, and M. A. Norcross. 1991. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J. Virol. 65:1543-1550.
3. Chou, J. H., and T.-C. Chou. 1989. Dose-effect analysis with microcomputers: quantitation of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics: a computer software for IBM-PC and manual. Biosoft, Cambridge, Mass.
4. Chou, T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.), Synergism and antagonism in chemotherapy. Academic Press, New York.
5. Chou, T.-C., and P. Talalay. 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme. Regul. 22:27-55.
6. Connor, R. I, D. W. Notermans, H. Mohri, Y. Cao, and D. D. Ho. 1993 Biological cloning of functionally diverse quasispecies of HIV-1. AIDS Res Hum. Retroviruses 9:541-546.
7. Cushman, M., S. Kanamathareddy, E. De Clercq, D. Schols, M. E. Goldman, and J. A. Bowen. 1991. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. J. Med Chem. 34:337-342.
8. Cushman, M., P. Wang, S. H. Chang, C. Wild, E. De Clercq, D. Schols. M. E. Goldman, and J. A. Bowen. 1991. Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J. Med. Chem. 34:329-337.
9. Dalgleish, A. G., P. C. L. Beverley, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (London) 312: 763-767.
10. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
11. Flexner, C., P. A. Barditch-Crovo, D. M. Kornhauser, H. Farzadegan, L. J. Nerhood, R. E. Chaisson, K. M. Bell, K. J. Lorentsen, C. W. Hendrix, B. G. Petty, and P. S. Lietman. 1991. Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection. Antimicrob. Agents Chemother 35:2544-2550.
12. Gartner, S., P. Markovits, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219.
13. Johnson, V. A., and R. E. Byingion. 1990 Modified HIV-1 p24 antigen ELISA. Quantitative assays for virus detection, p 95-97. In A. Aldovini and B. D. Walker (ed.). Techniques in HIV research. Stockton Press, New York
14. Johnson, V. A., D. P. Merrill. J. A. Videler, T.-C. Chou, R. E. Byington, J. J. Eron, R. T. D'Aquila, and M. S. Hirsch. 1991 Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect. Dis. 164:646-655
15. Klatzmann, U., E. Champagne, S. Chamaret, J. Gruest, D. Guetard, T. Hercend, J.-C. Gluckman, and L. Montagnier. 1984 T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (London) 312:767-768.
16. Lederman, S., J. E. Bergmann, A. M. Cleary, M. J. Yellin, P. J. Fusco, and L. Chess. 1992. Sulfated polyester interactions with the CD4 molecule and with the third variable loop domain (v3) of gp120 arc chemically distinct AIDS Res Hum. Retroviruses 8:1599-1610.
17. Meylan, P. R. A., R. S. Kornbluth, I. Zbinden, and D. D. Richman. 1994. Influence of host cell type and V3 loop of the surface glycoprotein on susceptibility of human immunodeficiency virus type 1 to polyanion compounds Antimicrob. Agents Chemother. 38:2910-2916.
18. Mohan, P., D. Schols, M. Baba, and E. De Clercq. 1992. Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors Antiviral Res. 18:139-150
19. Mohan, P., R. Singh, and M. Baba. 1991. Potential anti-AIDS agents. Synthesis and antiviral activity of naphthalcnesulfonic acid derivatives against HIV-1 and HIV-2 J Med Chem 34:212-217
20. 19a.National Institute of Allergy and Infectious Diseases, Division of AIDS. Unpublished data.
21. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
22. 20a.Procept, Inc. Unpublished data.
23. Ward, L. D. 1985. Measurement of ligand binding to proteins by fluorescence spectroscopy Methods Enzymol. 117:400-414